Mitesco, Biotech Stock Review, roland rick perry

Short Squeeze Mania.

Citius Pharma (CTXR) Locked and Loaded. Truly Locked and Loaded. Latest $20 Million Round is Biggest News We've Seen...
Internet Stock Review

Newsletter: Institutional Analyst. And Yes, We Have Another Double.

1. Dalrada (DFCO) $0.19. And Yes, We Have Another Double!2. Dyadic (DYAI) $6.40. We're Up 392%, Video Presentation.3....
Citius, Biotech Stock Review

Adding Citius Pharma (CTXR) $1.29 to the 2021 Biotech Portfolio.

The 2021 Biotech Six Pack, Six Stocks We Expect to Double. We're still putting the 2021 list together now,...

And We Have Our First MEME Stock! $2.00 to $29.95.

Tiny U.S. Biotech Jumps 930% as It Picks Up Retail Attention (Bloomberg) Guess we were bound to stumble across...
Citius, Leonard Mazur

Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.

https://youtu.be/vMIy8xWLOKI?t=3699 Starts at 1 Hour Mark. INSIDER HOLDINGS
cITIUS

Citius (CTXR) Announces Results of Mino-Lok Study.

"Mino-Lok has the potential to change the standard of care, which currently calls for a procedure to remove and replace the infected...
Biotech Stock Review, DYAI

Dyadic (DYAI) Scores $10M deal with Sorrento Therapeutics (SNRE).

Share Price up 27% ($4.63 up $1.04) as Wall Street Sorts out the Terms of the Deal. We've had...
Issam Radd

Citius (CTXR): Halt For Superiority On The Horizon? (SeekingAlpha).

Jun. 15, 2021 10:41 AM ET Citius Pharmaceuticals, Inc. (CTXR) Summary

Lantern Pharma (LTRN) $21.25 and Provention Bio (PRVB) $13.51 Added to Biotech Six Pack.

The 2021 Biotech Six Pack: Stocks We Expect to Double! These are ideas #3 and #4 for the 'Biotech...
American Brivision, Biotech Stock Review

American BriVision (ABVC) Reports Completion Clinical Trial for Treatment of Adult ADHD.

American BriVision (ABVC) Reports Completion of ABV-1505 Phase II Part I Clinical Trial for Treatment of Adult ADHD. Last...

Latest article

Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!

Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.

CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...